Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
But questions remain about both the Norse Two trial and the commercial opportunity.
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.